Search PubMed⌕ Search

Biomedical subjects

R A Robson

Publications and source records attributed to R A Robson.

82 records · Page 5Linked to original sources
PubMed1983

Serum profiles and safety of intermediate-dose (500-1,000 mg) methotrexate following IV and IM administration.

Despite extensive clinical experience with methotrexate there is no consensus of opinion as to the ideal method of administration. This study tested the hypotheses that intermediate-dose (500-1,000 mg) methotrexate can safely by administered to outpatients as an IM injection, and that similar serum profiles of methotrexate result from IM and IV administration. Fourteen patients received 500 mg methotrexate, and nine of these received 1,000 mg as an IM injection. Methotrexate levels at 24 and 48 h were below the levels at which toxicity can be expected. Six patients received 500 mg both IM and IV and 1,000 mg both IM and IV. Serum methotrexate profiles over 48 h were similar following both IM and IV administration. This study showed no evidence of significant toxicity in terms of bone marrow, gastrointestinal, or renal impairment.

Adult↗
PubMed1981

Sodium cromoglycate: spincaps or metered dose aerosol.

1 Sodium cromoglycate administered as a dry powder inhalation (20 mg/dose) via the Spinhaler was compared with a metered dose aerosol (2 mg/dose) in an eight week double dummy double blind crossover trial in 29 asthmatic children. 2 The powder formulation was associated with significantly less symptoms (night wheeze, night cough, day wheeze, day cough, activity) and bronchodilator intake; and significantly greater weight gain than aerosol therapy. There were no significant differences in morning or evening peak flow measurements on the two treatments. 3 The powder may be more effectively inhaled than the aerosol or the dose of the aerosol may not be large enough.

Adolescent↗
PubMed1979

Cancer of the large bowel in a defined population: Canterbury, New Zealand, 1970--4.

A total of 1024 new cases of cancer of the large bowel occurred in Canterbury, New Zealand (population 400,796), in the 5 years 1970--4. Of these, 992 were diagnosed before death and are reviewed in this paper. The high incidence of this disease in New Zealanders of European origin is illustrated. A significant difference in site distribution of primary tumours between the sexes was found, with a female preponderance of cancer of the proximal colon gradually changing to a male preponderance of cancer of the rectum. In all, 61.5 per cent of the patients had lymph node metastases or advanced disease at the time of diagnosis or treatment. Largely as a consequence of this, only 65 per cent were able to have potentially curative treatment. The estimated crude 5-year survival rate of the whole group was 32.7 per cent (relative rate 42.8 per cent) and the crude 5-year survival rate after potentially curative surgery was 48.4 per cent (relative rate 62.4 per cent). The results are compared with those of other authors. They emphasize the generally unsatisfactory outcome of treatment.

Adult↗
PubMedDate not supplied

Tinidazole pharmacokinetics in severe renal failure.

The single-dose pharmacokinetics of intravenously and orally administered tinidazole were studied in normal subjects and patients with severe chronic renal failure. The clearance of tinidazole was also measured in patients on regular haemodialysis. After intravenous administration the mean elimination half-life of tinidazole was 17.1 +/- 2.3 (SD) hours in the normal subjects and 16.9 +/- 4.9 hours in patients with renal failure; the mean apparent volumes of distribution were 0.80 +/- 0.09 L/kg and 0.69 +/- 0.09 L/kg, respectively. Following oral administration the mean elimination half-life was 15.6 +/- 1.6 hours in the normal subjects and 18.4 +/- 3.5 hours in patients with renal failure; there were no statistically significant differences in these pharmacokinetic parameters. There was no accumulation of the major metabolite (hydroxymethyl tinidazole) in normal subjects or in patients with renal failure. Tinidazole clearance during haemodialysis was 71 +/- 7.7 ml/min. In the presence of renal failure no modification of tinidazole dosage would appear to be necessary. Tinidazole should be administered in full dosage following haemodialysis.

Administration, Oral↗